Our founders were pioneers of monoclonal antibody therapy, bringing to the clinic the first humanised antibody, the first made in CHO cells, the first bispecific and the first aglycosylated antibody. Now we have developed a new Fc variant which is more comprehensively silenced than previous antibodies. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs. We are building partnerships with Universities, Biotech and Pharma companies to make this new technology widely available.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Oxford, Oxfordshire, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://mabsolve.com
- Keywords
- monoclonal antibodies, Fc fusion proteins, Fc receptors, antibody engineering, cytokine release, immunogenicity, complement, biotechnology, licensing.
- HQ
- Oxford, Oxfordshire
Mabsolve Questions
Mabsolve's website is https://mabsolve.com
Mabsolve's LinkedIn profile is https://uk.linkedin.com/company/mabsolve
Mabsolve has
6 employees.
View email and phone details for 6
employees at Mabsolve.
Mabsolve's industry is
Biotechnology Research
Mabsolve's top competitors are
Scancell,
Gamma Proteins,
Protein Stable,
Immunochem,
The Antibody Society,
Medimmune,
Qvq Holding Bv,
2bscientific Ltd.,
Absolute Antibody,
Afrobodies.
Mabsolve's categories are Biotechnology Research
Mabsolve's founding year is 2019
